Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHAWNASDAQ:ATNFWNASDAQ:LBPSWNASDAQ:XOMAP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAWAesther Healthcare Acquisition$0.01$0.01$0.06▼$0.33N/AN/A34,287 shsN/AATNFW180 Life Sciences$0.01-1.2%$0.01$0.00▼$0.04N/AN/A95,374 shs4,281 shsLBPSW4D pharma$0.00$0.04▼$1.29N/AN/A20,931 shsN/AXOMAPXOMA$25.44-2.0%$25.71$24.96▼$26.51N/AN/A1,702 shs2,836 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAWAesther Healthcare Acquisition0.00%-8.70%+30.43%-61.96%-80.94%ATNFW180 Life Sciences-1.22%-3.57%-13.83%+19.12%-19.80%LBPSW4D pharma0.00%0.00%0.00%0.00%0.00%XOMAPXOMA-1.97%-0.86%-1.59%-0.63%-3.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/AN/AN/AN/AXOMAPXOMAN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/AATNFW180 Life Sciences 0.00N/AN/AN/ALBPSW4D pharma 0.00N/AN/AN/AXOMAPXOMA 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/AN/ALBPSW4D pharma$522KN/AN/AN/AN/AN/AXOMAPXOMA$13.05MN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/A0.00N/AN/AN/AN/AN/AN/AXOMAPXOMAN/AN/A0.00∞N/AN/AN/AN/A8/11/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/AXOMAPXOMA$2.168.49%N/AN/AN/ALatest XOMAP, ATNFW, LBPSW, and AEHAW DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/21/2025XOMAPXOMAQuarterly$0.53918.45%7/3/20257/3/20257/15/2025(Data available from 1/1/2013 forward)Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAWAesther Healthcare AcquisitionN/AATNFW180 Life SciencesN/ALBPSW4D pharmaN/AXOMAPXOMAN/AInsider OwnershipCompanyInsider OwnershipAEHAWAesther Healthcare AcquisitionN/AATNFW180 Life SciencesN/ALBPSW4D pharmaN/AXOMAPXOMAN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableATNFW180 Life Sciences7N/AN/ANot OptionableLBPSW4D pharmaN/AN/AN/ANot OptionableXOMAPXOMA10N/AN/ANot OptionableXOMAP, ATNFW, LBPSW, and AEHAW HeadlinesRecent News About These CompaniesXOMA To Acquire Turnstone Biologics For $0.34/Shr Plus Contingent Value Right - NasdaqJune 29, 2025 | nasdaq.comResults: XOMA Royalty Corporation Exceeded Expectations And The Consensus Has Updated Its EstimatesMay 16, 2025 | finance.yahoo.comXOMA Royalty Corporation Common StockApril 26, 2025 | fxempire.comFBenchmark Initiates Coverage of XOMA Royalty (XOMA) with Buy RecommendationApril 17, 2025 | msn.comTrimble, Xoma announce new collaborationMarch 11, 2025 | markets.businessinsider.comHow to Take Advantage of moves in (XOMAP)January 30, 2025 | news.stocktradersdaily.comNXoma royalty corp sees sale of $16.98 million in stock by investorsJanuary 28, 2025 | msn.comXOMA Royalty CorporationJanuary 24, 2025 | seekingalpha.comHow to Take Advantage of moves in (XOMAO)January 8, 2025 | news.stocktradersdaily.comNXoma price target raised to $123 from $117 at H.C. WainwrightDecember 4, 2024 | markets.businessinsider.comXoma Royalty acquires Pulmokine for $20MDecember 2, 2024 | markets.businessinsider.comXOMA Royalty Corporation (XOMAP)November 21, 2024 | nz.finance.yahoo.comXoma’s Strategic Developments and Financial Performance Drive Buy Rating and Increased Price TargetNovember 11, 2024 | markets.businessinsider.comXoma (XOMA) Gets a Hold from TD CowenNovember 8, 2024 | markets.businessinsider.comXOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent ActivitiesNovember 7, 2024 | markets.businessinsider.comXOMA Royalty: Q3 Earnings SnapshotNovember 7, 2024 | finance.yahoo.comHow the (XOMA) price action is used to our AdvantageNovember 5, 2024 | news.stocktradersdaily.comNInvestors in XOMA Royalty (NASDAQ:XOMA) have seen favorable returns of 72% over the past yearOctober 21, 2024 | finance.yahoo.com(XOMAO) Proactive StrategiesOctober 14, 2024 | news.stocktradersdaily.comNParty Time: Brokers Just Made Major Increases To Their XOMA Royalty Corporation (NASDAQ:XOMA) Earnings ForecastsAugust 18, 2024 | finance.yahoo.comMedia Sentiment Over TimeXOMAP, ATNFW, LBPSW, and AEHAW Company DescriptionsAesther Healthcare Acquisition NASDAQ:AEHAW$0.0091 0.00 (0.00%) As of 07/2/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.180 Life Sciences NASDAQ:ATNFW$0.0081 0.00 (-1.22%) As of 07/3/2025 12:44 PM Eastern180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.4D pharma NASDAQ:LBPSW4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.XOMA NASDAQ:XOMAP$25.44 -0.51 (-1.97%) As of 07/3/2025 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
